Document is current

Article History

Received: 14 February 2025

Accepted: 12 May 2025

First Online: 4 June 2025

Declarations

:

: J.P.B. and B.M.B. are founders of Abceutics, Inc. which is pursuing development of payload binding agents to enhance the therapeutic selectivity of antibody–drug conjugates. J.P.B. and B.M.B. have financial interest through WO2021113740 A1. J.P.B. serves as the Director of the University at Buffalo Center for Protein Therapeutics, which is supported by an industry consortium. Through the consortium, J.P.B. has received research support, for work unrelated to this report, from Abbvie, Amgen, AstraZeneca, CSL-Behring, Eli Lilly, Genentech, GSK, Janssen, Merck, Roche, Sanofi, and Seagen. During the course of this work, J.P.B. has received consulting fees from companies involved with the development of cancer therapies, including: Abbvie, Amgen, Eli Lilly, Merck, and Pfizer.